CalciMedica is trading 5.16% up at $0.69 after closing at $0.66 on August 10, 2026, with no new company-specific announcement or clear overnight catalyst identified.

  • The latest major update remains the July 29 FDA alignment on Auxora’s acute-pancreatitis Phase 2b design.
  • Broader markets are modestly higher, but the Nasdaq’s 0.47% gain is insufficient to clearly explain the move.